What are the screening intervals and treatment recommendations for diabetic retinopathy, nephropathy, and peripheral neuropathy in type 1 and type 2 diabetes?

Microvascular Complications of Diabetes: Screening and Management

Diabetic Retinopathy

Screening Intervals

All patients with type 1 diabetes should undergo their first dilated eye examination within 5 years of diagnosis, while those with type 2 diabetes should be screened at the time of diagnosis. 1

• Annual screening is the standard for most patients with diabetes who have minimal or no retinopathy. 1
• Screening intervals may be extended to every 1-2 years after one or more normal examinations in well-controlled patients, though annual remains safest in routine practice. 1
• More frequent examinations (every trimester during pregnancy and for 1 year postpartum) are required for pregnant women with pre-existing type 1 or type 2 diabetes, as pregnancy accelerates retinopathy progression. 1

Treatment Recommendations

Promptly refer patients with any level of macular edema, severe nonproliferative diabetic retinopathy (NPDR), or any proliferative diabetic retinopathy (PDR) to an ophthalmologist experienced in diabetic retinopathy management. 1

• Anti-VEGF therapy (ranibizumab, FDA-approved in 2017) has replaced laser photocoagulation as first-line treatment for diabetic macular edema, improving vision in the vast majority of patients. 1
• Panretinal photocoagulation surgery reduces severe vision loss from PDR from 15.9% to 6.4%, with greatest benefit in those with disc neovascularization or vitreous hemorrhage. 1
• Most patients require near-monthly intravitreal anti-VEGF injections during the first 12 months, with fewer injections needed subsequently. 1

Adjunctive Therapy

• Control blood pressure to <130/80 mmHg to decrease retinopathy progression; however, targets <120 mmHg systolic provide no additional benefit. 1
• Add fenofibrate in patients with dyslipidemia and very mild nonproliferative diabetic retinopathy, as it slows progression. 1
• Optimize glycemic control to near-normoglycemia to prevent onset and slow progression of retinopathy. 1

---

Diabetic Nephropathy

Screening Intervals

Screen all patients with type 2 diabetes for albuminuria at diagnosis and annually thereafter; begin screening patients with type 1 diabetes 5 years after diagnosis and continue annually. 1

• Measure urine albumin excretion to detect levels ≥30 mg/24 hours (moderately elevated albuminuria) or ≥300 mg/24 hours (severely elevated albuminuria). 1
• When estimated glomerular filtration rate (eGFR) falls below 60 mL/min/1.73 m², evaluate and manage potential complications of chronic kidney disease. 1

Treatment Recommendations

Prescribe either ACE inhibitors or ARBs (but never both in combination) for nonpregnant patients with urinary albumin excretion ≥30 mg/24 hours. 1

• ACE inhibitors and ARBs are not recommended for primary prevention in patients with normal blood pressure and albumin excretion <30 mg/24 hours. 1
• Monitor serum creatinine and potassium when using ACE inhibitors, ARBs, or diuretics to detect increased creatinine or electrolyte changes. 1
• Continue monitoring urine albumin excretion to assess treatment response and disease progression. 1
• Reducing dietary protein below usual intake does not alter glycemic measures, cardiovascular risk, or GFR decline and is not recommended. 1
• Refer to a nephrologist for uncertain etiology, difficult management issues, or advanced kidney disease. 1

---

Diabetic Peripheral Neuropathy

Screening Intervals

Screen all patients with type 2 diabetes for diabetic peripheral neuropathy (DPN) at diagnosis and patients with type 1 diabetes 5 years after diagnosis, then continue screening at least annually using simple clinical tests. 1

Diagnostic Assessment

Perform a focused neurologic examination that evaluates both small-fiber function (pinprick and temperature sensation) and large-fiber function (vibration with 128-Hz tuning fork and ankle reflexes). 1, 2

• Conduct annual 10-g monofilament testing at multiple plantar foot sites to identify loss of protective sensation (LOPS), which markedly increases the risk of foot ulceration and amputation. 1, 2, 3
• Assessment should start distally at the dorsal aspect of the great toe and move proximally until threshold is detected. 1
• Up to 50% of diabetic peripheral neuropathy may be asymptomatic, making systematic screening essential. 2, 3
• Electrophysiological testing or neurologist referral is rarely needed except when clinical features are atypical or diagnosis is unclear. 1

Exclusion of Alternative Causes

Diabetic neuropathy is a diagnosis of exclusion—always evaluate for treatable causes including vitamin B12 deficiency (especially in metformin users), hypothyroidism, neurotoxic medications, alcohol abuse, renal disease, malignancies, infections (HIV), chronic inflammatory demyelinating neuropathy, inherited neuropathies, and vasculitis. 1, 2

Treatment Recommendations

Initiate first-line neuropathic pain therapy immediately with pregabalin, duloxetine, or gabapentin while simultaneously optimizing glycemic control. 2

Agent Selection

• Duloxetine 60 mg daily is preferred for patients with comorbid depression, providing 30-50% reduction in pain intensity with potential improvement in numbness and tingling. 2
• Gabapentin titrated to 1200 mg daily (divided three times daily) yields ≥50% pain reduction in approximately 38% of patients and is the most cost-effective first-line option. 2
• Pregabalin 150-300 mg daily (divided twice daily) is FDA-approved specifically for diabetic neuropathic pain, with a number needed to treat of 4.0-5.9 for ≥50% pain reduction. 2

Opioid Restrictions

• Reserve tramadol or stronger opioids only for refractory pain; avoid routine use because of addiction risk and insufficient long-term efficacy data. 2

Disease-Modifying Interventions

• Tight glycemic control is the only strategy convincingly shown to prevent or delay DPN development in type 1 diabetes and slow progression in type 2 diabetes. 1, 2
• Achieve individualized HbA1c targets of 6-7% based on age, comorbidities, and hypoglycemia risk; avoid rapid HbA1c reduction in severely elevated cases, as this can paradoxically worsen neuropathic symptoms. 2
• Aggressively control blood pressure to <130/80 mmHg and manage dyslipidemia, as these factors significantly contribute to neuropathy progression in type 2 diabetes. 2

Preventive Foot Care

• Educate all patients to perform daily foot inspection for cuts, blisters, pressure points, or color changes to reduce ulcer risk. 2
• Provide general foot self-care education to all patients with diabetes. 1
• Refer patients who smoke, have LOPS and structural abnormalities, or have a history of prior ulcer or amputation to foot care specialists for ongoing preventive care and lifelong surveillance. 1
• A multidisciplinary approach is recommended for individuals with foot ulcers and high-risk feet. 1

---

Diabetic Autonomic Neuropathy

Screening and Assessment

Assess for autonomic neuropathy symptoms at each visit, including orthostatic hypotension (dizziness, syncope), resting tachycardia, gastroparesis (erratic glucose control, early satiety, nausea), erectile dysfunction, and bladder dysfunction. 1, 2, 3

• Screening for cardiovascular autonomic neuropathy (CAN) should be considered at diagnosis of type 2 diabetes and 5 years after diagnosis of type 1 diabetes, particularly in patients with more advanced disease. 1
• Cardiac autonomic neuropathy is associated with mortality independently of other cardiovascular risk factors. 4

---

Common Pitfalls and Caveats

• Do not prescribe nitrofurantoin for urinary tract infections in diabetic patients, as it significantly increases neuropathy risk. 2
• Do not rapidly lower HbA1c if severely elevated, as this can paradoxically worsen neuropathic symptoms and accelerate retinopathy progression. 1, 2
• Do not delay neuropathic pain treatment while waiting for electrodiagnostic studies. 2
• Do not overlook vitamin B12 deficiency, especially in metformin users, as deficiency compounds neuropathy risk. 2
• Women with gestational diabetes mellitus do not require eye examinations during pregnancy and do not appear at increased risk of developing diabetic retinopathy during pregnancy. 1
• The presence of retinopathy is not a contraindication to aspirin therapy for cardioprotection, as aspirin does not increase the risk of retinal hemorrhage. 1